The 50-day moving average for ALEC moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALEC as a result. In 86 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ALEC turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ALEC moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALEC crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ALEC entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.495) is normal, around the industry mean (3.043). P/E Ratio (-1.679) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The RSI Indicator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 23 of the 27 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 28 of 39 cases over the following month. The odds of a continued upward trend are 72%.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.294) is normal, around the industry mean (4.801). AXON has a moderately high P/E Ratio (170.190) as compared to the industry average of (16.610). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
ALEC | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 69 | |
SMR RATING 1..100 | 100 | 81 | |
PRICE GROWTH RATING 1..100 | 55 | 63 | |
P/E GROWTH RATING 1..100 | 75 | 45 | |
SEASONALITY SCORE 1..100 | 90 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALEC's Valuation (8) in the Biotechnology industry is significantly better than the same rating for AXON (93). This means that ALEC’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as ALEC (100). This means that AXON’s stock grew similarly to ALEC’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as ALEC (100). This means that AXON’s stock grew similarly to ALEC’s over the last 12 months.
ALEC's Price Growth Rating (55) in the Biotechnology industry is in the same range as AXON (63). This means that ALEC’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (45) in the Biotechnology industry is in the same range as ALEC (75). This means that AXON’s stock grew similarly to ALEC’s over the last 12 months.
| ALEC | AXON | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 70% |
| Momentum ODDS (%) | 1 day ago 87% | N/A |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 72% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 76% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 71% |
| Advances ODDS (%) | 5 days ago 84% | 1 day ago 74% |
| Declines ODDS (%) | 3 days ago 86% | 6 days ago 70% |
| BollingerBands ODDS (%) | N/A | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 59% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALEC’s FA Score shows that 1 FA rating(s) are green while AXON’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALEC’s TA Score shows that 3 TA indicator(s) are bullish while AXON’s TA Score has 4 bullish TA indicator(s).
ALEC (@Biotechnology) experienced а -0.54% price change this week, while AXON (@Aerospace & Defense) price change was +7.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.11%. For the same industry, the average monthly price growth was -15.47%, and the average quarterly price growth was -17.72%.
ALEC is expected to report earnings on Nov 05, 2026.
AXON is expected to report earnings on Nov 03, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Aerospace & Defense (-1.11% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EIPX | 33.57 | 0.50 | +1.51% |
| FT Energy Income Partners Strategy ETF (EIPX) | |||
| FLAO | 28.80 | N/A | N/A |
| AllianzIM U.S. Equity 6 Month Floor5 Apr/Oct ETF (FLAO) | |||
| GMOD | 27.65 | -0.09 | -0.32% |
| GMO Dynamic Allocation ETF (GMOD) | |||
| SLYG | 107.59 | -0.40 | -0.37% |
| State Street SPDR S&P 600 Small Cap Growth ETF (SLYG) | |||
| TSLT | 13.65 | -0.20 | -1.44% |
| T-REX 2X Long Tesla Daily Target ETF (TSLT) | |||